Thermo,
Based on the status of this investment I was wondering if, given the scale of your group's investment here, whether you would be willing to share some financial modeling guidelines you use.
In my experience as a pharma industry person I am used to calculations like 10 x EBITDA or 3 x peak sales when valuing a company or new product with peak sales being a key that is often not understood.
There are several dynamics here that can limit the valuation such as time though it is difficult to imagine the valuation of a company that can address all solid tumors. The IP is limited as mfg patents are less secure and competition will be fierce and probably already ramping up in this technology space given these results. Time will be of the essence now and NWBO will need to move more rapidly to their platform development strategy. There needs to be direct correlation between the MOA of DCVax and other solid cancers to enable approval risk probabilities, which still needs some deep study.
Also, I see a strategic partnership as the probable move for NWBO to allow time to accelerate development and demonstrate value, though the partnership may be very profitable for NWBO.
Any thoughts you are willing to share would be appreciated, and sorry if you already have and I missed them.
Good luck to you and all here, every week is now looking more and more interesting
Market Data 
Markets 
AI
